Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Japan and Astellas Pharma have decided to amend their co-promotion deal which was signed in August 2009 for Caduet Combination Tablets which is indicated as a treatment of hypertension and hypercholesterolemia.
Subscribe to our email newsletter
Caduet Combination Tablets are oral combination drug of Norbasc Tablets and Lipitor Tablets.
Under the agreement, Pfizer is responsible to seek marketing approval for the product in Japan, effective 1 October 2011.
According to the new agreement, Astellas will acquire all the distribution rights of Caduet Combination Tablets from 1 October 2011 and will book its sales which are currently booked by Pfizer.
Additionally, Astellas will advance its promotional activity to enhance the product value of Caduet Combination Tablets.